JP2016520289A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520289A5
JP2016520289A5 JP2016502049A JP2016502049A JP2016520289A5 JP 2016520289 A5 JP2016520289 A5 JP 2016520289A5 JP 2016502049 A JP2016502049 A JP 2016502049A JP 2016502049 A JP2016502049 A JP 2016502049A JP 2016520289 A5 JP2016520289 A5 JP 2016520289A5
Authority
JP
Japan
Prior art keywords
seq
sequence
polynucleotide
level
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016502049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026094 external-priority patent/WO2014151606A2/en
Publication of JP2016520289A publication Critical patent/JP2016520289A/ja
Publication of JP2016520289A5 publication Critical patent/JP2016520289A5/ja
Withdrawn legal-status Critical Current

Links

JP2016502049A 2013-03-15 2014-03-13 膵臓癌の治療方法 Withdrawn JP2016520289A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794788P 2013-03-15 2013-03-15
US61/794,788 2013-03-15
PCT/US2014/026094 WO2014151606A2 (en) 2013-03-15 2014-03-13 Methods of treating pancreatic cancer

Publications (2)

Publication Number Publication Date
JP2016520289A JP2016520289A (ja) 2016-07-14
JP2016520289A5 true JP2016520289A5 (https=) 2017-04-13

Family

ID=51581651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502049A Withdrawn JP2016520289A (ja) 2013-03-15 2014-03-13 膵臓癌の治療方法

Country Status (11)

Country Link
US (1) US20160030561A1 (https=)
EP (1) EP2971146A4 (https=)
JP (1) JP2016520289A (https=)
KR (1) KR20150130466A (https=)
CN (1) CN105051215A (https=)
AU (1) AU2014233736A1 (https=)
CA (1) CA2900969A1 (https=)
HK (1) HK1211322A1 (https=)
IL (1) IL240688A0 (https=)
MX (1) MX2015011386A (https=)
WO (1) WO2014151606A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
US20190309369A1 (en) * 2016-05-09 2019-10-10 Inserm (Institute National De La Sante Et De La Recherche Medicale) Methods for classifying patients with a solid cancer
EP3595717A1 (en) * 2017-03-17 2020-01-22 Imclone, LLC Combination therapy for pancreatic cancer
KR20200005540A (ko) * 2017-04-14 2020-01-15 제넨테크, 인크. 암의 진단 및 치료 방법
WO2019203255A1 (ja) * 2018-04-19 2019-10-24 公立大学法人横浜市立大学 再構成癌組織を用いた薬剤評価方法
WO2023225345A1 (en) * 2022-05-20 2023-11-23 Mayo Foundation For Medical Education And Research Treating chemoresistant cancers with notch3 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102390A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch3 expression
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US7807630B2 (en) * 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
CN104402998A (zh) * 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
US9062311B2 (en) * 2009-01-26 2015-06-23 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL
CA2775880A1 (en) * 2009-09-30 2011-04-07 Genentech, Inc. Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias

Similar Documents

Publication Publication Date Title
JP2016520289A5 (https=)
Jain et al. Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
Allanore et al. Systemic sclerosis
JP5727484B2 (ja) Ｉ型インターフェロン診断法
JP2017501137A5 (https=)
WO2014151606A4 (en) Methods of treating pancreatic cancer
JP2022125079A (ja) がん転移の予後診断および処置のための方法
ES2529593T3 (es) Marcadores de enfermedades y usos de los mismos
JP2020062012A (ja) 神経膠芽腫を治療するための診断方法及び組成物
CN105980576B (zh) 用于源自乳腺癌的骨转移癌的预后和治疗的方法
CA2726691C (en) Use of oncogene nrf2 for cancer prognosis
JP2016105731A5 (https=)
JP2018078911A5 (https=)
WO2015084808A4 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors
JP2018506045A5 (https=)
US20200108066A1 (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
KR20170094165A (ko) 화학요법-내성 암을 치료 및 진단하는 조성물 및 방법
TR201819859T4 (tr) Akciğer kanseri metastazının tanısı ve prognozu için yöntem.
JP2017523776A (ja) 膠芽腫の診断方法及びその治療用組成物
JP2017511131A5 (https=)
JP2019523641A5 (https=)
JP2017517507A5 (https=)
Tian et al. Expression and prognostic significance of CCL11/CCR3 in glioblastoma
JP2017527533A5 (https=)
JP2018508532A5 (https=)